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Abstract Two multicentre external quality assessments
(EQA) for the molecular detection and genotyping of
meticillin-resistant Staphylococcus aureus (MRSA) were
arranged. Firstly, 11 samples containing various amounts of
inactivated MRSA strains, meticillin-susceptible S. aureus
(MSSA), meticillin-resistant coagulase-negative staphylo-
cocci (MRCoNS) or Escherichia coli were distributed to 82
laboratories. Samples containing 102 or 103 MRSA cells
were correctly scored in only 16 and 46% of the datasets
returned, respectively. Two of the used MSSA strains
contained an SCCmec cassette lacking the mecA gene.
There was a marked difference in the percentage of correct
results for these two MSSA strains (37 and 39%) compared
to the MSSA strain lacking the SCCmec cassette (88%).
Secondly, a panel for MRSA genotyping, consisting of ten
samples (two identical, three genetically related and five
unique strains) was distributed to 19 laboratories. Seventy-
three percent of the datasets recorded all samples correctly.
Most pulsed-field gel electrophoresis (PFGE) protocols
proved to be suboptimal, resulting in inferior resolution in
the higher or lower fragment regions. The performance of
molecular diagnostics for MRSA shows no significant
changes since our first EQA in 2006. The first molecular
typing results are encouraging. Both assessments indicate
that programme expansion is required and that major
performance discrepancies continue to exist.
Introduction
Adequate infection control of meticillin-resistant Staphy-
lococcus aureus (MRSA) strongly depends on the speed
and quality of (molecular) identification and character-
isation strategies used by the clinical microbiological
laboratory [1, 2].
Over the past 4–5 decades, cultivation assays have been
primarily used for the detection and subsequent identification
of MRSA. However, cultivation requires prolonged incuba-
tion periods and, in general, clinically relevant meticillin
resistance still needs to be confirmed by the detection of the
mecA gene or its product. Nucleic acid amplification
techniques (NAATs) offer benefits over traditional culture-
based assays, in particular, a reduced time to identification
and an improved specificity and sensitivity. Over the past
decade, a range of commercial and in-house developed
NAATs has been introduced. The sensitivity and specificity
of these assays may be compromised, as a result of inhibition
or false-positivity due to the presence of meticillin-resistant
coagulase negative staphylococci (MRCoNS) or variability
within the mec-resistance cassette. This may lead to false-
negative results (new staphylococcal cassette chromosome
mec [SCCmec] variants) or false-positive results (deletion of
the mecA gene) [3–6].
After MRSA detection, genetic typing may be necessary
in order to assess whether local cross-infection occurs and
whether preventive measurements are mandatory. Current-
ly, many different genotyping methods are in use in the
diagnostic laboratory, but pulsed-field gel electrophoresis
(PFGE) of SmaI digested genomic DNA still remains the
most frequently used method [7]. Only when outbreaks are
properly defined, adequate infection control measurements
can be implemented.
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The current multicentre external quality assessment
(EQA) study determined the performance of molecular
assays to detect MRSA and genotyping techniques to
differentiate MRSA strains. The studies were coordinated
by Quality Control for Molecular Diagnostics (QCMD) in
Glasgow, Scotland.
Material and methods
EQA for molecular MRSA detection and identification
In August 2009, the EQA MRSA panel for MRSA
detection and identification was distributed to 80 partici-
pating laboratories in 15 countries, along with detailed
sample processing instructions. Participants were given
6 weeks to examine the samples and to report their results
to the QCMD by using an online data collection system.
The QCMD MRSA panel consisted of six samples
containing 106, 105 (n=2), 104, 103 and 102CFU/ml MRSA
bacterial cells, one meticillin-susceptible S. aureus (MSSA)
sample, one sample containing MRCoNS, two samples
containing MSSA harbouring an SCCmec cassette lacking
the mecA gene and one sample containing Escherichia coli
(Table 1). The production laboratory quantified the contents
of the samples on the basis of colony counting, optical
density measurements and real-time molecular amplifica-
tion results. All bacterial samples were heat-inactivated for
10 min at 100°C.
EQA for MRSA genotyping
The EQA panel for MRSA genotyping was distributed to
19 participants in eight countries in August 2009. The
panel consisted of ten samples of viable MRSA strains in
Müller Hinton broth. Genetic relatedness of the MRSA
panel was originally determined with PFGE [8]. The
current panel consisted of two identical strains, three
genetically related strains and five unique strains (Table 2).
Genotype and subtype were reported by the production
laboratory. A different letter signifies the detection of a
different genotype, whereas a different number signifies
the detection of a different subtype. All data were reported
in relation to the reference strain in panel sample
MRSATP09-01.
The QCMD Neutral Office analysed the data, which was
anonymously released to all participants in a detailed EQA
final report.
Results
EQA for molecular MRSA detection and identification
Out of the 80 participants, 68 (85%) responded. Twelve
participants did not return results. Five of these withdrew
officially, indicating ‘assay not offered’ (n=2), ‘internal
issues’ (n=1) and ‘other’ (n=2) as the reason for
withdrawal.
Table 1 Composition of the QCMD 2009 panel for MRSA detection and identification
Sample Sample content Target value (CFU/ml) Sample status
MRSA09-01 MRCoNS c 1×107 Negative
MRSA09-02 MSSA d 5×106 Negative
MRSA09-03 MSSA b 5×106 Negative
MRSA09-04 MRSA a 5×105 Positive
MRSA09-05 MRSA a 5×106 Positive
MRSA09-06 MRSA a 2.5×102 Positive
MRSA09-07 MRSA a 2.5×104 Positive
MRSA09-08 MRSA a 5×105 Positive
MRSA09-09 MSSA e 1×107 Negative
MRSA09-10 MRSA a 2.5×103 Positive
MRSA09-11 E. coli f 5×106 Negative
MRSA a: meticillin-resistant Staphylococcus aureus N315
MSSA b: meticillin-sensitive Staphylococcus aureus ATCC 29213
MRCoNS c: meticillin-resistant coagulase-negative staphylococci 634
MSSA d: meticillin-sensitive Staphylococcus aureus (MecA negative 92-1866 [SSCmec III])
MSSA e: meticillin-sensitive Staphylococcus aureus (MecA negative 93-2886 [SCCmec I])
E. coli f: Escherichia coli ATCC 35218
296 Eur J Clin Microbiol Infect Dis (2010) 29:295–300
The following commercial amplification assays were
used for MRSA detection: BAG HealthCare Hyplex
StaphyloResist (n=1) (BAG Healthcare, Lich, Germany),
BD Diagnostic GeneOhm MRSA Assay (n=13) (BD
Diagnostics, GeneOhm, San Diego, California), BD Diag-
nostics GeneOhm Staph SR Assay (n=5) (BD Diagnostics ,
GeneOhm), Cepheid IDI MRSA (n=1) (Cepheid, Sunny-
vale, California), Cepheid Xpert MRSA Test (n=11)
(Cepheid), Cepheid Xpert MRSA/SATest (n=2) (Cepheid),
Roche LightCycler MRSA Advanced Test (n=4) (Roche
Sample Expected genotype Total datasets PFGE a AFLP b spa c
n=15 n=11 n=2 n=2
n % n % n % n %
MRSATP09-01 A 15 100 11 100 2 100 2 100
MRSATP09-02 B 11 73.3 8 72.7 1 50.0 2 100
MRSATP09-03 C 14 93.3 11 100 1 50.0 2 100
MRSATP09-04 D 14 93.3 11 100 1 50.0 2 100
MRSATP09-05 A 13 86.7 10 90.9 1 50.0 2 100
MRSATP09-06 E 13 86.7 11 100 2 100 0 0.0
MRSATP09-07 F 12 80.0 9 81.8 1 50.0 2 100
MRSATP09-08 G 14 93.3 11 100 1 50.0 2 100
MRSATP09-09 G1 11 73.3 11 100 0 0.0 0 0.0
MRSATP09-10 G2 11 73.3 11 100 0 0.0 0 0.0
Table 2 Genotyping results per
panel member and technology
type of the QCMD 2009 panel
for MRSA genotyping
PFGE a: BioRad GenePath
group 1 reagent kit (n=2), in-
house PFGE (n=8) and double-
locus sequence typing (n=1)
AFLP b: in-house AFLP (n=2)
spa c: in-house spa typing (n=2)
Table 3 Number of correct qualitative results per panel member and technology type
Sample Sample content Total datasets PCR NASBA e Other f
Conventional Real-time
Commercial a In-house b Commercial c In-house d
n=82 n=1 n=3 n=45 n=30 n=1 n=2
n % n % n % n % n % n % n %
MRSA09-05 MRSA 82 100 1 100 3 100 45 100 30 100 1 100 2 100
MRSA09-04 MRSA 82 100 1 100 3 100 45 100 30 100 1 100 2 100
MRSA09-08 MRSA 81 98.8 1 100 3 100 44 97.8 30 100 1 100 2 100
MRSA09-07 MRSA 80 97.6 1 100 3 100 45 100 28 93.3 1 100 2 100
MRSA09-10 MRSA 38 46.3 0 0.0 2 66.7 22 48.9 13 43.3 0 0.0 1 50.0
MRSA09-06 MRSA 13 15.9 0 0.0 0 0.0 6 13.3 6 20.0 0 0.0 1 50.0
MRSA09-03 MSSA 72 87.8 1 100 3 100 40 88.9 25 83.3 1 100 2 100
MRSA09-09 MSSA 30 36.6 1 100 3 100 5 11.1 20 66.7 1 100 0 0.0
MRSA09-02 MSSA 32 39.0 1 100 3 100 5 11.1 22 73.3 1 100 0 0.0
MRSA09-01 MRCoNS 66 80.5 0 0.0 2 66.7 40 88.9 21 70.0 1 100 2 100
MRSA09-11 E. coli 73 89.0 1 100 1 33.3 39 86.7 29 96.7 1 100 2 100
Commercial a: BAG HealthCare Hyplex Staphyloresist (n=1)
In-house b: details not presented
Commercial c: BD Diagnostics, details not provided (n=7), BD Diagnostics GeneOhm MRSA Assay (n=13), BD Diagnostics GeneOhm Staph
SR Assay (n=5),Cepheid IDI MRSA (n=1), Cepheid Xpert MRSATest (n=11), Cepheid Xpert MRSA/SATest (n=2), Roche LightCycler MRSA
Advanced Test (n=4),TIB MolBiol LightMix Kit MRSA (n=2)
In-house d: details not presented
NASBA e: details not presented
Other f: Hain Lifescience GenoQuick MRSA (n=2)
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Diagnostics, Basel, Switzerland), TIB MOLBIOL LightMix
Kit MRSA (n=2) (TIB MolBiol, Berlin, Germany) and
Hain Lifescience GenoQuick MRSA (n=2) (Hain Life-
science, Nehren, Germany). This diversity overlaps with
the spectrum of currently available commercial tests.
All results are summarised in Table 3. Results for the
panel samples with 106 MRSA cells (MRSA09-05), 105
MRSA cells (MRSA09-04 and MRSA09-08) and 104
MRSA cells (MRSA09-07) were reported correctly in
100, 100, 99 and 98% of the datasets, respectively. The
samples containing lower amounts, MRSA09-10 (103CFU/
ml) and MRSA09-06 (102CFU/ml), were reported correctly
in only 46 and 16% of the datasets, respectively. No
statistically significant differences in sensitivity or specific-
ity could be seen between the different tests or between
commercial and in-house testing. MRCoNS sample
MRSA09-01 was correctly reported as MRSA-negative by
87% (40 out of 46) of the commercial polymerase chain
reaction (PCR) tests and in 70% (23 out of 33) of the in-
house PCR assays. MSSA sample MRSA09-03 was
correctly reported as MRSA-negative by 89% (41 out of
46) of commercial PCR tests and in 85% (28 out of 33) of
datasets generated by in-house PCR assays, respectively.
The MSSA samples containing the SCCmec cassette but
lacking the mecA gene (MRSA09-02 and MRSA09-09)
were both incorrectly reported as positive by commercial
PCR tests in 87% (40 out of 46). For in-house assays, these
samples were reported incorrectly in 24% (8 out of 33) and
30% (10 out of 33), respectively. These percentages of
incorrect results underline the need for improved specificity
of these MRSA tests and, therefore, positive results should
always be confirmed by a culture method or a second
molecular test. For laboratories with high false-positivity
rates or in regions with a low prevalence of MRSA,
confirmation is essential [9]. For the E. coli sample,
commercial PCR results were reported correctly in 87%
(39 out of 45), whereas in-house PCR tests recorded correct
results in 97% (29 out of 30).
EQA for MRSA genotyping
Out of the 19 potential participants, 14 (74%) responded.
Four of the non-responders withdrew officially, indicating
‘panel used for research’ (n=1) and ‘assay not offered’ (n=
3). The majority of datasets were generated by PFGE (n=
11), with the remainder generated by AFLP (n=2) and spa
typing (n=2). Only eight participants (73%) scored all
samples correctly, all with PFGE (Table 2).
Discussion
To maintain high-quality clinical care, quality control of
molecular diagnostics is very important. The primary aim
of our EQA programmes was to assess the proficiency of
laboratories in the molecular detection and characterisation
of MRSA strains. Here, we conclude that the molecular
detection of MRSA in samples with high CFU counts is
Sample content Sample concentration (CFU/ml) Percentage of correct results
2006 2007 2008 2009
MRSA a 1×109 96.6 96.3 93.2 NIP
MRSA a 5×106 82.8 96.3 91.9 100
MRSA a 5×105 NIP NIP NIP 100
MRSA a 5×105 NIP NIP NIP 98.8
MRSA a 2.5×104 NIP NIP NIP 97.6
MRSA a 2.5×103 51.7 72.2 54.1 46.3
MRSA a 1×103 51.7 66.7 55.4 NIP
MRSA a 2.5×102 12.1 37.0 20.3 15.9
MSSA b 1×109 87.9 92.6 89.2 NIP
MSSA b 5×106 NIP NIP NIP 87.8
MSSA b 1×103 NIP 94.4 95.9 NIP
MRCoNS c 1×107 82.8 88.9 94.6 80.5
MSSA b + MRCoNS c 1×103+1×105 94.8 83.3 86.5 NIP
MSSA b + MRCoNS c 1×103+1×104 96.6 77.8 83.8 NIP
MSSA d 5×106 NIP NIP NIP 36.6
MSSA e 1×107 NIP NIP NIP 39.0
E. coli f 5×106 93.1 92.6 97.3 89.0
S. aureus negative medium – NIP 92.6 98.6 NIP
Table 4 Comparison of perfor-
mance on like samples in the
QCMD 2006, 2007, 2008 and
2009 MRSA EQA programmes
NIP: not in panel
MRSA a: meticillin-resistant
Staphylococcus aureus N315
MSSA b: meticillin-sensitive
Staphylococcus aureus ATCC
29213
MRCoNS c: meticillin-resistant
coagulase-negative staphylococci
634
MSSA d: meticillin-sensitive
Staphylococcus aureus (MecA
negative 92-1866 [SSCmec III])
MSSA e: meticillin-sensitive
Staphylococcus aureus (MecA
negative 93-2886 [SCCmec I])
E. coli f: Escherichia coli ATCC
35218
S. aureus negative medium:
Müller Hinton broth.
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reliable, which can, and has been, implemented in various
laboratory settings with confidence. All tests performed
equally well. However, for direct molecular diagnostics, we
have to conclude that current commercial and in-house tests
do not meet the required quality criteria. The sensitivity of
many tests is relatively low and the specificity needs to be
improved. The FDA submission in 2004 of the IDI-MRSA
test had a detection limit of 325 CFU/swab [10]. This is
much more sensitive than documented in this study. Pre-
enrichment of clinical samples leads to concentrations of
MRSA exceeding 109CFU/ml, which is higher than the
concentrations of MRSA likely to be found in a patient
sample and also those in this EQA panel. However, pre-
enrichment reduces one of the major advantages offered by
NAATs, namely, rapidity. In this year’s panel, only
inactivated cells were present. As a consequence, pre-
enrichment was not possible. This may have influenced the
results of some laboratories. For the years to come, viable
cells will be distributed, which is more similar to the real
clinical situation.
This is the fourth year that the QCMD has offered the
MRSA DNA EQA Programme and the number of
participants has increased from 51 in 2006, 61 in 2007
and 74 in 2008 to 80 in 2009 [11]. Over the years, we
observe a statistically non-significant decrease in the overall
test sensitivity. The most pronounced discrepancies were
observed in the low-concentration panel samples (103 and
102CFU/ml). Conversely, the percentage of correct results
showed an overall improvement for the ‘specificity’
samples (containing MSSA and MRCoNS or E. coli) and
the ‘true-negative’ samples (Table 4). Again, this was not
statistically significant. Still, these incorrect results under-
line the need for improved specificity of molecular MRSA
tests and, therefore, positive results should always be
confirmed by a culture method or a second molecular test.
For laboratories with high false-positivity rates or in regions
with a low prevalence of MRSA, confirmation is necessary.
In 2009, two MSSA samples harbouring an SCCmec
cassette, but lacking the mecA gene, were included. There
was a marked difference in the percentage of correct
qualitative results for the MSSA strain containing the mecA
gene compared to the two strains lacking it. These data
show that confirmation on results generated using assays
that only target the SCCmec cassette is mandatory.
In conclusion, the quality of molecular diagnostic tests
still needs improvement, and proper and regular quality
control and international standardisation for MRSA diag-
nostics should be mandatory for the years to come.
We present the first QCMD EQA programme for the
genetic characterisation of MRSA strains. Clear differences
in resolution were observed between the datasets. Some
PFGE protocols, which were implemented by most of the
participating laboratories, proved to be suboptimal, as a low
level of discrimination in the high and/or low molecular
weight fragments was observed in the majority of the
results reported. This suggests the need for optimisation of
the PFGE programme. This lack of resolution was most
evident within the group of closely related MRSA strains in
the panel (MRSATP09-08, MRSATP09-09 and MRSA09-
10). These strains were incorrectly reported in 27% of
datasets. Participants reported using a range of criteria for
determining genotype and subtype. The guidance according
to Tenover et al. was the most prominent method [12].
To improve the performance and quality of molecular
diagnostics, both laboratories and manufacturers should be
encouraged to participate in EQAs. The availability of EQA
panels for detection and typing should also be developed for
other important (nosocomial) infectious agents, including
vancomycin-resistant enterococci (VRE) and extended-
spectrum β-lactamase (ESBL)-producing enterobacteriaceae.
Acknowledgements We acknowledge Deborah Kreft for her tech-
nical assistance in the preparation of the panels.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Brown DF, Edwards DI, Hawkey PM, Morrison D, Ridgway GL,
Towner KJ, Wren MW (2005) Guidelines for the laboratory
diagnosis and susceptibility testing of methicillin-resistant Staphylo-
coccus aureus (MRSA). J Antimicrob Chemother 56(6):1000–1018
2. Weller TM (2000) Methicillin-resistant Staphylococcus aureus
typing methods: which should be the international standard? J
Hosp Infect 44(3):160–172
3. Ibrahem S, Salmenlinna S, Virolainen A, Kerttula AM, Lyytikäi-
nen O, Jägerroos H, Broas M, Vuopio-Varkila J (2009) Carriage
of methicillin-resistant Staphylococci and their SCCmec types in a
long-term-care facility. J Clin Microbiol 47(1):32–37
4. Bartels MD, Boye K, Rohde SM, Larsen AR, Torfs H, Bouchy P,
Skov R, Westh H (2009) A common variant of staphylococcal
cassette chromosome mec type IVa in isolates from Copenhagen,
Denmark, is not detected by the BD GeneOhm methicillin-resistant
Staphylococcus aureus assay. J Clin Microbiol 47(5):1524–1527
5. Jansen WT, Beitsma MM, Koeman CJ, van Wamel WJ, Verhoef J,
Fluit AC (2006) Novel mobile variants of staphylococcal cassette
chromosome mec in Staphylococcus aureus. Antimicrob Agents
Chemother 50(6):2072–2078
6. Ender M, Berger-Bächi B, McCallum N (2007) Variability in
SCCmecN1 spreading among injection drug users in Zurich,
Switzerland. BMC Microbiol 7:62
7. Ichiyama S, Ohta M, Shimokata K, Kato N, Takeuchi J (1991)
Genomic DNA fingerprinting by pulsed-field gel electrophoresis
as an epidemiological marker for study of nosocomial infections
caused by methicillin-resistant Staphylococcus aureus. J Clin
Microbiol 29(12):2690–2695
8. van Belkum A, van Leeuwen W, Kaufmann ME, Cookson B, Forey
F, Etienne J, Goering R, Tenover F, Steward C, O'Brien F, Grubb
W, Tassios P, Legakis N, Morvan A, El Solh N, de Ryck R,
Eur J Clin Microbiol Infect Dis (2010) 29:295–300 299
Struelens M, Salmenlinna S, Vuopio-Varkila J, Kooistra M, Talens
A, Witte W, Verbrugh H (1998) Assessment of resolution and
intercenter reproducibility of results of genotyping Staphylococcus
aureus by pulsed-field gel electrophoresis of SmaI macrorestriction
fragments: a multicenter study. J Clin Microbiol 36(6):1653–1659
9. Kerremans JJ, Maaskant J, Verbrugh HA, van LeeuwenWB, VosMC
(2008) Detection of methicillin-resistant Staphylococcus aureus in a
low-prevalence setting by polymerase chain reaction with a selective
enrichment broth. Diagn Microbiol Infect Dis 61(4):396–401
10. Huletsky A, Giroux R, Rossbach V, Gagnon M, Vaillancourt M,
Bernier M, Gagnon F, Truchon K, Bastien M, Picard FJ, van
Belkum A, Ouellette M, Roy PH, Bergeron MG (2004) New real-
time PCR assay for rapid detection of methicillin-resistant
Staphylococcus aureus directly from specimens containing a
mixture of staphylococci. J Clin Microbiol 42(5):1875–1884
11. van Belkum A, Niesters HG, MacKay WG, van Leeuwen WB
(2007) Quality control of direct molecular diagnostics for
methicillin-resistant Staphylococcus aureus. J Clin Microbiol 45
(8):2698–2700
12. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE,
Persing DH, Swaminathan B (1995) Interpreting chromosomal
DNA restriction patterns produced by pulsed-field gel electropho-
resis: criteria for bacterial strain typing. J Clin Microbiol 33
(9):2233–2239
300 Eur J Clin Microbiol Infect Dis (2010) 29:295–300
